The gene editing field has exploded in the last ten years, with methods such as CRISPR-Cas9 becoming well-established in the pre-clinical sphere. However, complications in clinical applications have led some researchers to explore alternatives.

Study suggests the haplotype number for hepatitis B virus could act as a predictive biomarker for functional cure during antiviral therapies.

The first ever potential biomarker for Parkinson’s disease has been discovered.

Discovery of a new sensitive urinary biomarker could pave the way for cost-effective and large-scale screening of neurodegenerative disease.

New hope raised for the early detection and treatment of the tick-borne illness.

A new study analysing the cholesterol levels of black adults challenges traditional perceptions of its role in predicting heart disease risk.

On-Demand Webinar featuring Dr Alessio Colombo, Application Scientist at Akoya

On-Demand Webinar featuring Dr Elizabeth Crone, Business Development Manager at Owlstone & Dr Hsuan (Tina) Chou, Biomarker Scientist at Owlstone

Current and upcoming gene editing technologies, such as prime editing and cell line models, have huge potential in applications such as cancer treatment. With the field constantly witnessing new breakthroughs and advances, genome modification holds a lot of promise for the future.

Cancer-related cognitive impairment in young adults found pre-treatment, study reports.

Unique neuroinflammatory signatures and pathways present in tauopathies could provide greater insight into distinct mechanisms of disease.

How can we better define patient-centric clinical trials within the drug development process?